Has Kenneth Rodriguez received payments from drug or device companies?

Yes. Drug and device makers reported $20,691 in general payments to Kenneth Rodriguez across 382 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kenneth Rodriguez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kenneth Rodriguez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kenneth Rodriguez

Endocrinology, Diabetes & Metabolism · Maitland, FLNPI 1912337924

Payments from drug & device makers

$20,691in general payments, 2019–2025

Across 382 payments — averaging $54.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Chiesi USA, Inc.$7K
Sanofi-aventis U.S. LLC$4K
Tandem Diabetes Care, Inc.$2K
Lilly USA, LLC$1K
Novo Nordisk$1K
Amgen$679
plus $5K from 39 others

What the payments were for

Consulting fees$2,20011%
Speaking & faculty fees$7,52836%
Travel & lodging$9254%
Food & beverage$9,93748%
Education$410%
Gifts$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Chiesi USA, Inc.	9	$6,633
Sanofi-aventis U.S. LLC	36	$4,041
Tandem Diabetes Care, Inc.	16	$2,092
Lilly USA, LLC	42	$1,201
Novo Nordisk	58	$1,170
Amgen(2 entities)	16	$679
Corcept Therapeutics	15	$428
Sanofi	3	$362
Boehringer Ingelheim	20	$314
Abbott	10	$283
AbbVie	15	$281
IBSA Pharma Inc.	13	$254
Bayer	9	$241
AstraZeneca	9	$240
Amneal Pharmaceuticals LLC	13	$203
Cequr Corporation	1	$187
Amarin Pharma, Inc.	13	$185
Companion Medical, Inc.	2	$183
Johnson & Johnson	11	$160
Antares Pharma, Inc.	9	$156
Xeris Pharmaceuticals, Inc.	7	$146
Radius Health, Inc.	6	$143
Merck	11	$140
BETA Bionics, Inc.	4	$92
Echosens North America, Inc.	2	$84
Mannkind Corporation	2	$75
Shire North American Group Inc	1	$71
Kyowa Kirin, Inc.	4	$71
Rhythm Pharmaceuticals, Inc.	2	$65
Pfizer	3	$59
Ipsen Biopharmaceuticals, Inc	1	$50
Madrigal Pharmaceuticals	2	$46
Insulet Corporation	1	$45
Amphastar Pharmaceuticals, Inc.	2	$45
Ascensia Diabetes Care US Inc.	2	$42
Dexcom, Inc.	2	$33
Ascendis Pharma Endocrinology Inc	1	$29
Medtronic(2 entities)	2	$27
Sequel Med Tech, LLC	1	$27
Globus Medical	1	$25
Halozyme Inc	1	$19
Averitas Pharma Inc.	1	$17
Renalytix AI, Inc.	1	$16
Ferring Pharmaceuticals Inc.	1	$16
Axonics, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,691 in reported general payments places this provider in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	73	$95,062
MounjaroTirzepatide	38	$45,963
TrulicityDulaglutide	27	$39,480
JardianceEmpagliflozin	37	$33,934
Humulin R U-500 KwikpenInsulin Regular, Human	15	$31,107
Tresiba Flextouch U-200Insulin Degludec	12	$20,418
JanuviaSitagliptin Phosphate	27	$14,941
MyrbetriqMirabegron	14	$5,775
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	16	$3,618
SynthroidLevothyroxine Sodium	35	$3,493
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	11	$1,403
Hydrocortisone	14	$1,073
Levothyroxine Sodium	56	$596
Metformin Hcl	64	$548
Atorvastatin Calcium	27	$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$1,170	$95,06273 claims
Lilly USA, LLCMounjaro, Trulicity	$1,201	$85,44365 claims
Boehringer IngelheimJardiance	$314	$33,93437 claims
MerckJanuvia	$140	$14,94127 claims
AbbVieSynthroid	$281	$3,49335 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium	$203	$59656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Maitland

Richard PratleyOrlando$9.2M
Jose MandryOcoee$9.1M
Steven SmithOrlando$7.9M
Barry HorowitzWest Palm Beach$7.1M
Tina ThethiOrlando$3.8M
David SuttonJacksonville$3.1M
Lorena Lewy-AlterbaumHollywood$3.1M
Mae Sheikh AliJacksonville$2.9M
James MageeJacksonville$2.7M
Rodolfo GalindoMiami$2.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →